Evaluation of neoadjuvant therapy for pancreatic cancer: is it the best choice? / 中华消化外科杂志
Chinese Journal of Digestive Surgery
;
(12): 41-45, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-865010
ABSTRACT
Currently the treatment strategy of pancreatic cancer has shifted from the mode "surgery first" to multidisciplinary team.More and more evidences have revealed that neoadjurant therapy will help to increase the R0 resection rate,reduce the recurrence rate,and improve the prognosis of the patients with borderline resectable pancreatic cancer.Furthermore,neoadjuvant therapy is also recommended for resectable pancreatic cancer patients with high risk factors of tumor recurrence.In this article,the current controversy and research progress of neoadjuvant therapy for pancreatic cancer are reviewed and commented in order to deepen the understanding of the hot topic in clinial surgeons.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Idioma:
Chinês
Revista:
Chinese Journal of Digestive Surgery
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS